Pasar al contenido principal

FUNCION DIFERENCIAL DE LA MITOCONDRIA EN NEURONA-ASTROCITO DEPENDIENTE DE A-SINUCLEINA EN LA ENFERMEDAD DE PARKINSON

PID2022-137065OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

RIPK1 expression and inhibition in tauopathies: implications for neuroinflammation and neuroprotection

  • Silva-Llanes, Ignacio
  • Madruga, Enrique
  • Martínez Gil, Ana
  • Lastres-Becker, Isabel
11 p.-3 fig., Tauopathies are a group of neurodegenerative diseases characterized by the alteration/aggregation of TAU protein. One of the main challenges of these diseases is that they have neither biomarkers nor pharmacological targets to stop the neurodegenerative process. Apart from the neurodegenerative process, tauopathies are also characterized by a chronic low-grade neuroinflammation process, where the receptor-interacting protein kinase 1 (RIPK1) protein plays an essential role. Our research aimed to explore the role of RIPK1 in various tauopathies. We examined mouse models of frontotemporal dementia (FTD), as well as brain tissue samples from patients with progressive supranuclear palsy (PSP), a primary form of 4R tauopathy, and Alzheimer’s disease (AD), which is considered a secondary tauopathy. Our findings show elevated levels of RIPK1 mRNA levels across various forms of tauopathies, in both mouse models and human tissue samples associated with primary and secondary TAU-related disorders. Furthermore, we investigated the potential of using a RIPK1 inhibitor, known as GSK2982772, in a mouse model as a novel treatment strategy for FTD. The data showed that GSK2982772 treatment effectively reduced the reactive astrocyte response triggered by TAUP301L overexpression. However, this RIPK1 inhibitor failed to protect against the neurodegeneration caused by elevated TAUP301L levels in the hippocampal region. These results suggest that although inhibiting RIPK1 activity may help reduce TAU-related astrogliosis in the brain, the complexity of the inflammatory pathways involved could explain the absence of neuroprotective effects against TAU-induced neurodegeneration., This work was supported by MINECO (grants PID2019-105600RB-I00 to A.M. and I.L-B, and PID2022-137065OB-I00 to I.L-B), ISCiii CIBERNED (CB06/05/0089 to IL-B and CB18/05/00040 to AM and EM)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Beneficial Effect of Dimethyl Fumarate Drug Repositioning in a Mouse Model of TDP-43-Dependent Frontotemporal Dementia

  • Silva-Llanes, Ignacio
  • Martín-Baquero, Raquel
  • Berrojo-Armisen, Alicia
  • Rodríguez-Cueto, Carmen
  • Fernández-Ruiz, Javier
  • Lago, Eva de
  • Lastres-Becker, Isabel
Frontotemporal dementia (FTD) causes progressive neurodegeneration in the frontal and temporal lobes, leading to behavioral, cognitive, and language impairments. With no effective treatment available, exploring new therapeutic approaches is critical. Recent research highlights the transcription factor Nuclear Factor erythroid-derived 2-like 2 (NRF2) as vital in limiting neurodegeneration, with its activation shown to mitigate FTD-related processes like inflammation. Dimethyl fumarate (DMF), an NRF2 activator, has demonstrated neuroprotective effects in a TAU-dependent FTD mouse model, reducing neurodegeneration and inflammation. This suggests DMF repositioning potential for FTD treatment. Until now, no trial had been conducted to analyze the effect of DMF on TDP-43-dependent FTD. In this study, we aimed to determine the potential therapeutic efficacy of DMF in a TDP-43-related FTD mouse model that exhibits early cognitive impairment. Mice received oral DMF treatment every other day from presymptomatic to symptomatic stages. By post-natal day (PND) 60, an improvement in cognitive function is already evident, becoming even more pronounced by PND90. This cognitive enhancement correlates with the neuroprotection observed in the dentate gyrus and a reduction in astrogliosis in the stratum lacunosum-moleculare zone. At the prefrontal cortex (PFC) level, a neuroprotective effect of DMF is also observed, accompanied by a reduction in astrogliosis. Collectively, our results suggest a potential therapeutic application of DMF for patients with TDP-43-dependent FTD., This work was supported MINECO (PID2019-105600RB-I00 and PID2022-137065OB-I00 to I.L.-B. and PID2021-128906OB-I00 to E.D.L./J.F.-R.) and ISCiii CIBERNED (CB06/05/0089 to I.L.-B./E.D.L./J.F.-R.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Investigation in the cannabigerol derivative VCE-003.2 as a disease-modifying agent in a mouse model of experimental synucleinopathy

  • Burgaz, Sonia
  • Navarro, Elisa
  • Rodríguez-Carreiro, Santiago
  • Navarrete, Carmen
  • Garrido-Rodríguez, Martín
  • Lastres-Becker, Isabel
  • Chocarro, Julia
  • Lanciego, José Luis
  • Muñoz, Eduardo
  • Fernández-Ruiz, Javier
This work has been supported by grants from CIBERNED (CB06/05/0089 to JF-R), MICINN (PID2021-128906OB-I00 to JF-R, PID2022-139936OA-I00 to EN and PID2022-137065OB-I00 to ILB) with FEDER funds and Michael J. Fox Foundation (MJFF-022552 to JF-R). These agencies had no further role in study design, the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the paper for publication. Sonia Burgaz was a predoctoral fellow supported by the Complutense University, whereas Santiago Rodríguez-Carreiro was supported by the Ministry of University (FPU Programme)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting CB2 receptor with a novel antagonist reverses cognitive decline, neurodegeneration and pyroptosis in a TAU-dependent frontotemporal dementia mouse model

  • Silva-Llanes, Ignacio
  • Rodríguez-López, S.
  • González-Naranjo, Pedro
  • Sastre, E. del
  • López, Manuela G.
  • Páez, Juan A.
  • Campillo, Nuria
  • Lastres-Becker, Isabel
Frontotemporal dementia (FTD) comprises a group of disorders characterized by a progressive decline in behavior or language linked to the degeneration of the frontal and anterior temporal lobes followed by hippocampal atrophy. There are no effective treatments for FTD and for this reason, novel pharmacological targets, such as the endocannabinoid system (ECS), are being explored. Previous results from our laboratory showed a TAU-dependent increase in CB receptor expression in hippocampal neurons of a FTD mouse model, alongside the neuroprotective impact of CB ablation. In this study, we evaluated the therapeutic potential of a new CB antagonist (PGN36) in our TAU-dependent FTD mouse model. Six-month-old mice received stereotaxic injections of an adeno-associated virus expressing human TAU protein (AAV-TAU) into the right hippocampus and were treated daily with PGN36 (5 mg/kg, i.p.) or vehicle for three weeks. By integrating behavioral tests, RNA-seq, qPCR expression analysis, and immunofluorescence in the AAV expressing TAU mouse model, we found that PGN36 treatment reverses key features of the neurodegenerative process triggered by TAU overexpression. PGN36 treatment effectively countered TAU-induced cognitive decline by reducing TAU protein expression levels and restoring markers of synaptic plasticity. Notably, we observed neuroprotection in the dentate gyrus granular layer, which we attribute to the modulation of pyroptosis. This programmed cell death pathway, is triggered by TAU overexpression. PGN36 appears to modulate the pyroptotic cascade, thereby preventing the pyroptosis-induced neuronal loss. These findings collectively underscore the neuroprotective potential of this novel CB antagonist treatment against TAU-associated FTD., This work was supported by Fundación Tatiana Pérez de Guzmán el Bueno, MINECO (grants PID2019-105600RB-I00 and PID2022- 137065OB-I00 to I.L-B and PDC2022-133809-I00 to MGL), ISCiii CIBERNED (CB06/05/0089 to I. L-B.) and Community of Madrid ref CAM-P2022/BMD-7230 to MGL. FPU18/00630 contract to ES.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Transcription factor NRF2: New therapeutic approach to modify Parkinson's disease progression

  • Rojo, Ana I.
  • Esteras, Noemí
  • Cuadrado, Antonio
  • Lastres Becker, Isabel
The lack of neuroprotective therapies for Parkinson's disease (PD) is a critical issue with significant societal and scientific relevance. The medications available, such as levodopa and dopamine agonists, focus solely on managing symptoms by temporarily replenishing dopamine or mimicking its effects. While these treatments provide relief, they do not address the root cause of the disease, allowing neurodegeneration to continue unchecked. This is why it is necessary to find new therapeutic targets that slow down the progression of the neurodegenerative process. The search for a single target capable of modulating oxidative stress, neuroinflammation, and the alteration of proteostasis associated with PD has focused on the transcription factor NRF2. Genetic variations in the NRF2 encoding NFE2L2 gene promoter that may influence disease risk and onset age have been associated with disease risk or prevention. This basic leucine-zipper protein orchestrates the expression of a battery of cytoprotective genes, all of which share a specific enhancer known as the antioxidant response element (ARE). These genes are pivotal in a variety of cellular processes, including detoxification reactions across phases I, II, and III, metabolism of glutathione and the peroxiredoxin/thioredoxin system, NADPH generation, neuroinflammation, iron management/ferroptosis, and proteostasis. Given NRF2's ability to modulate several PD's key features, various pharmacological approaches have been explored. This chapter examines the role of NRF2 in PD pathogenesis and discusses promising compounds validated in mouse models that warrant clinical trial, This work was supported by MINECO (Grants PID2022-137065OB-I00 to I.L.-B.; PID-2021-122766OB-100, PDC2021-121421-I00, PDC2022-133765-I00 to AIR and AC; PID2022-137011OA-I00/AEI/10.13039/501100011033/FEDER, EU to NE), ISCiii CIBERNED (CB06/05/0089 to IL-B and NE; CB06/05/0010 to AC and AIR) and the Autonomous Community of Madrid (P2022/BMD-7230) to AIR and AC. NE is funded by a Ramón y Cajal Fellowship (RYC2021-034267-I) from the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033., Peer reviewed